

## Acconeer - Short-Term Weakness but Long-Term View Intact

Redeye states that the Q1 report was a disappointment in terms of financial figures - with both sales and the number of customer launches well below Redeye's expectations. Redeye does, however, not change its perception about where Acconeer will be a few years out. While the road from cSEK10m to above SEK100m revenues per quarter is steep, there will inevitably be bumps on the road to get there. Redeye thinks Q1 was one such bump. Additionally, Redeye estimates that Acconeer will need additional financial of SEK100-150m in H2'23. Redeye makes minor adjustments to its fair value range.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

**Acconeer - Short-Term Weakness but Long-Term View Intact**